Squarepoint Ops LLC Buys Shares of 475,571 Roivant Sciences Ltd. $ROIV

Squarepoint Ops LLC acquired a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 475,571 shares of the company's stock, valued at approximately $16,830,000. Squarepoint Ops LLC owned about 0.07% of Roivant Sciences at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Morgan Stanley lifted its position in shares of Roivant Sciences by 31.7% during the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company's stock valued at $1,266,402,000 after buying an additional 14,036,696 shares during the last quarter. Rubric Capital Management LP raised its stake in shares of Roivant Sciences by 14.7% during the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company's stock worth $229,574,000 after acquiring an additional 2,603,260 shares in the last quarter. State Street Corp lifted its position in Roivant Sciences by 4.8% during the second quarter. State Street Corp now owns 19,773,480 shares of the company's stock valued at $222,847,000 after acquiring an additional 911,827 shares during the last quarter. California State Teachers Retirement System boosted its stake in Roivant Sciences by 4,212.2% in the second quarter. California State Teachers Retirement System now owns 19,001,068 shares of the company's stock valued at $672,448,000 after acquiring an additional 18,560,434 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Roivant Sciences by 365.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company's stock valued at $238,323,000 after acquiring an additional 8,621,567 shares in the last quarter. Institutional investors own 64.76% of the company's stock.

Roivant Sciences Stock Up 0.8%

Roivant Sciences stock opened at $41.81 on Thursday. The business's 50-day moving average price is $35.56 and its 200 day moving average price is $31.46. The firm has a market cap of $30.20 billion, a price-to-earnings ratio of -78.89 and a beta of 1.12. Roivant Sciences Ltd. has a 52 week low of $13.40 and a 52 week high of $42.50.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. The firm had revenue of $1.44 million during the quarter, compared to analysts' expectations of $2.06 million. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. Equities analysts expect that Roivant Sciences Ltd. will post -2 EPS for the current year.

Roivant Sciences News Roundup

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Roivant’s Pulmovant unit reported positive Phase 2 PHocus results for mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD). The treatment produced a 56.3% placebo-adjusted reduction in pulmonary vascular resistance, supporting the drug’s potential in a serious disease with substantial unmet need. Roivant PHocus study announcement
• Positive Sentiment: Roivant has started the Phase 3 PHrontier trial, advancing mosliciguat toward a potential registration-enabling study. The transition to late-stage development reduces some development uncertainty and increases the potential value of the program. Mosliciguat Phase 3 trial report
• Positive Sentiment: Analysts raised their price targets while maintaining buy ratings: Jefferies increased its target to $52 from $42, and HC Wainwright raised its target to $47 from $41. These revisions indicate increased confidence in Roivant’s pipeline and commercial prospects.
• Positive Sentiment: Unusually heavy call-option activity and reports that hedge-fund holdings rose 41% added to bullish trading momentum, although options activity is a market-positioning signal rather than a fundamental change. Roivant hedge fund holdings report
• Positive Sentiment: Roivant and partner Priovant are also commercializing Lisraya, described as the first oral FDA-approved treatment for dermatomyositis, with a reported list price of $35,000 per 30-day supply. The launch creates another potential revenue stream, though uptake and reimbursement remain important uncertainties.
• Neutral Sentiment: Management presented at the Wells Fargo and Cantor Fitzgerald healthcare conferences, giving investors additional updates on the pipeline and strategy. The available reports do not identify a separate material announcement from those presentations. Cantor Fitzgerald conference transcript

Analyst Ratings Changes

A number of analysts have recently weighed in on ROIV shares. Cantor Fitzgerald reissued an "overweight" rating on shares of Roivant Sciences in a research report on Tuesday, August 25th. Guggenheim raised their price target on Roivant Sciences from $42.00 to $46.00 and gave the stock a "buy" rating in a report on Wednesday. Jefferies Financial Group boosted their price target on Roivant Sciences from $42.00 to $52.00 and gave the stock a "buy" rating in a research note on Tuesday. HC Wainwright upped their price objective on shares of Roivant Sciences from $41.00 to $47.00 and gave the company a "buy" rating in a report on Tuesday. Finally, Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a research report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $40.62.

Insider Activity

In other Roivant Sciences news, Director Daniel Gold sold 12,380 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $35.28, for a total transaction of $436,766.40. Following the transaction, the director owned 13,689,166 shares in the company, valued at approximately $482,953,776.48. This represents a 0.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Melissa Epperly sold 17,750 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $34.38, for a total value of $610,245.00. Following the transaction, the director owned 16,474 shares in the company, valued at $566,376.12. This trade represents a 51.86% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 3,055,913 shares of company stock valued at $107,261,258. Insiders own 8.80% of the company's stock.

Roivant Sciences Profile

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions.

Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support.

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.